Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Bilcare Limited

NSE: BIHealthcare Research, Analytics & TechnologyTrade-to-trade true

Share price

₹94.72

+1.99% close of 9 Oct 2026

Market cap ₹227 CrP/E 11.4

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 5 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

36

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹227 Cr

P/E ratio

11.4

P/B ratio

1.1

ROCE

7.1%

ROE

1.5%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹112.4552-week low ₹51.94

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales fell 0.9% over the past year. Meanwhile what it keeps of every 100 rupees of sales improved from 7.0% to 8.6% over the last four years.

Whether it grew faster than its sector

It grew 1.1% a year against a sector median of 13.1% — 12.0 percentage points slower.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 0.4 times its growth rate, on earnings growth of 32%.

Profit growthPrice per ₹1 profitPer 1% growth
Bilcare Limited — this one32%/yr11.4×₹0.36
Syngene International Limited-8%/yr47.5×—
Indegene Limited16%/yr33.5×₹2.1
Suven Life Sciences Limited———
Vimta Labs Limited19%/yr30.2×₹1.6
Fabtech Technologies Limited19%/yr12.2×₹0.64

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Healthcare Research, Analytics & Technology), it ranks 6 of 7 on returns, 5 of 6 on growth, 5 of 7 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 7.1% on capital, ahead of 14% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹310 crore of cash from the business, spent ₹35 crore on plant and equipment, and returned ₹341 crore to lenders and shareholders. It has not made a profit over 12 years.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

5 of 7 checks clear · 71%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 13 Aug 2026 · Consolidated · Unaudited

Revenue

₹226 Cr

Revenue vs last year

+21.2%

Revenue vs last quarter

+20.4%

Net profit

₹15 Cr

Profit vs last quarter

+87.1%

Net margin

6.6%

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹227 Cr
Prev close
₹94.72
52w High
₹116
52w Low
₹50.0
Enterprise value
₹841 Cr
Beta
1.0
Price CAGR 1y
15.0%
Price CAGR 3y
6.0%
Price CAGR 5y
7.0%
Price CAGR 10y
4.0%

Ratios

Return on assets
-2.0%
PEG ratio
0.3
P/E ratio
11.4
P/B ratio
1.1
EV / EBITDA
12.0
Industry P/E
31.6
ROCE
7.1%
ROCE 5y average
3.6%
ROE
1.5%
Debt / Equity
3.1
Interest coverage
0.7
Dividend yield
0.0%
ROE 3y average
-3.0%
ROE last year
1.0%

Annual P&L

Annual revenue
₹734 Cr
Annual profit
-₹17 Cr
Operating margin
6.0%
Net profit margin
-2.3%
EBITDA margin
6.1%
Sales growth 3y
-9.2%
Sales growth 5y
3.3%
Profit growth 3y
32.0%
Profit growth 5y
16.0%
EPS
₹0.7
Sales growth TTM
-1.0%
Profit growth TTM
248.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹226 Cr
Profit latest quarter
₹15 Cr
YoY quarterly sales growth
21.2%
YoY quarterly profit growth
—
OPM latest quarter
16.4%

Balance Sheet

Book Value
₹82.1
Face Value
₹10.0
Total debt
₹620 Cr
Total cash
₹6 Cr
Borrowings
₹620 Cr
Reserves / Equity
7.2

Cash Flow

Operating cash flow
₹128 Cr
Free cash flow
₹120 Cr
FCF yield
21.1%
Net cash flow
-₹10 Cr

Shareholding

Promoter holding
30.0%
FII holding
0.0%
DII holding
—
Public holding
69.9%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Syngene Intl.357.5048.714,4310.35-9.0-94.9736.0-15.810.0
Indegene597.5034.514,3950.38116.2-0.21,063.139.718.8
Suven Life Scie.306.108,6490.00-127.6-147.73.690.9-79.5
Vimta Labs572.0531.72,5570.3421.011.4109.111.825.2
Fabtech Tech.143.0013.16360.424.2154.875.010.313.6
Bilcare94.7711.22230.0015.0473.1225.921.27.1
Novelix Pharma.67.7053.21930.001.2972.736.965.210.9
Median143.0033.16360.001.2117.475.030.510.9

Competes with: Fabtech Technologies Limited, Indegene Limited, Suven Life Sciences Limited, Syngene International Limited, Take Solutions Limited, Vimta Labs Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales182190175200194202198194186178181188226
Expenses169173158208175194187186175175168171189
Material Cost143
Change in Inventories-3.48
Purchases of Stock-in-Trade0
Employee Cost20
Other Expenses30
Operating Profit131717-8198118113131737
OPM %7.398.799.86-4.139.763.795.383.965.941.927.189.0216
Other Income31494-6-621643120
Exceptional items (within Other Income)-1.74
Interest19202123212419191919171818
Depreciation1010111312111251212554
Profit before tax-13-13-10-35-10-33-276-13-24-6715
Tax %-1-534-4455-10-40-119-25-13-13-1
Net Profit-13-12-14-20-15-30-1612-10-23-6815
EPS in Rs-3.36-3.22-2.91-4.63-2.71-6.81-3.047.47-1.61-5.250.415.685.39

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,6922,6032,6332,7782,9971,827623845982747788734773
Expenses2,5062,3962,4432,6172,8271,782572784925708742689703
Operating Profit1862071901611704551605739464570
OPM %787662.508765669
Other Income9-8710729759254454423716122620
Interest23615117624928317476696082827272
Depreciation19116417741637823946393845182026
Profit before tax-232-194-56-207-433-114-25-4196-72-43-21-7
Tax %-7-5842-45-13-55374-18-35-19
Net Profit-216-82-80-199-453-99-11-450-59-28-17-6
EPS in Rs-92-36-36-85-193-44-8.95-5.356.39-14-0.330.736.23
Dividend Payout %000000000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
-12%
5 years
3%
3 years
-9%
TTM
-1%

Compounded profit growth

10 years
-14%
5 years
16%
3 years
32%
TTM
248%

Stock price CAGR

10 years
4%
5 years
7%
3 years
6%
1 year
15%

Return on equity

10 years
-50%
5 years
-6%
3 years
-3%
Last year
1%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital242424242424242424242424
Reserves1,073689590376-93856352507474191173
Borrowings2,3112,1222,0142,0892,270707677690639756689620
Other Liabilities9337868309138882973003624243142126
Total Liabilities4,3403,6203,4573,4023,0871,1121,0641,1271,5931,568924843
Fixed Assets1,9262,4322,4032,1802,0055344944651,0451,038456432
CWIP2181611491707900111410
Investments01010000281114
Other Assets2,1961,0269041,0511,003577570661545521453387
Total Assets4,3403,6203,4573,4023,0871,1121,0641,1271,5931,568924843

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-315177300982062567241-76286128
Cash from Investing Activity247-358-129-203-1041,3092-436-10681-5
Cash from Financing Activity119149-15591-103-1,600-83-55-1936-171-132
Net Cash Flow50-3216-13-1-35-9-1810-7-3-10
Free Cash Flow-74-12165-115911,569693711-34141120

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1253529383822909570735554
Inventory Days10510884908228908342778086
Days Payable93868110271359310277705770
Cash Conversion Cycle1375732254915887634807869
Working Capital Days1255-11-150-156-2-19-10-1012-528
ROCE %122-8-6-9333147

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters303030303030303030303030
FIIs0.040.040.040.040.040.040.040.040.040.040.040.04
Public707070707070707070707070
No. of Shareholders19,87519,18119,11618,78318,24118,49617,58617,04716,51316,06815,82415,777

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +3.0% (₹91.93 → ₹94.72)Brick size ₹3.69 (fixed)Bricks 45
₹60.00₹80.00₹100₹94.72Nov '25Jan '26Mar '26May '26Aug '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹94.72 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

10.01cr

2026-06-30

total loans / revolving facilities outstanding at period end, the base of loan_default_cr

10.83cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

614inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Bilcare Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Healthcare Research, Analytics & Technology
Classification
Healthcare › Healthcare Research, Analytics & Technology
ISIN
INE986A01012

Plants

  • Shiroli, Rajgurunagar works

News impact

Big market events that reach Bilcare Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Bulk & block deals

DateWhoBought / soldSharesPrice
7 Sep 2026GUTTIKONDA VARA LAKSHMIBUY1,25,814₹100.64
19 Aug 2026GUTTIKONDA VARA LAKSHMISELL1,92,861₹96.96

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.